Published research on Praziquantel

2 peer-reviewed publications on Praziquantel in oncology research, clinical work first, then laboratory studies. Each entry reports what the authors stated; follow the link for the full paper.

This page is a reading list of peer-reviewed publications, compiled for information. It is not a statement of indications, a recommendation or medical advice. Results from cell and animal studies do not translate into clinical use. Medsuvac products are supplied for their registered purposes; clinical decisions belong to a qualified physician.

In vivo
Combination of Praziquantel and Aspirin Minimizes Liver Pathology of Hamster Opisthorchis viverrini Infection Associated Cholangiocarcinoma

Sudsarn P et al., Pathology and Oncology Research, 2016

In hamsters with Opisthorchis viverrini infection and N-nitrosodimethylamine exposure, combined praziquantel and aspirin treatment reduced inflammatory infiltration, bile duct proliferation, fibrosis and cholangiocarcinoma area, and 37.5% of animals in that group did not develop cholangiocarcinoma.
In vivo
Praziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growth

Wu ZH et al., PLoS One, 2012

Praziquantel synergistically enhanced paclitaxel-induced growth inhibition in several cancer cell lines, including paclitaxel-resistant lines, induced mitotic arrest and apoptosis, and the combination inhibited tumor growth more than either drug alone in a mouse xenograft model, with XIAP downregulation required for the effect.

Praziquantel in the catalog (specifications, pack sizes, Certificate of Analysis)